It doesn't matter where we trade today or whether
Post# of 148184
In 2-3 weeks, CYDY will trade based on fundamentals (CD-12 results).
This will be a $20+ stock with PE met and following EUA.
If PE is missed, but great clinical significance is shown, we might be in for a wild ride and a sell-off at first, reflecting uncertainty regarding what FDA will do, with a potential reversal following.
If CD-12 is a complete fail, we will see pre-covid SP levels.
We will know soon enough which one it'll be... My money is still on option 1 obviously, although I must say I am getting nervous, since I wish for a clear and indisputable success, but a ~33% RRR to meet PE is a relatively high hurdle, especially since effFDA only allowed two doses.